Stocks in play: InnoCan Pharma Corp

Announces the launch of its licensing and commercialization strategy work with respect to cannabinoid (CBD) therapy in the veterinary field. The appointment of a dedicated internal team will foster engagement between Innocan and prospective clients in the veterinary field in order to explore potential collaborations and commercialization opportunities. Innocan's innovative CBD-based products have previously demonstrated promise in human clinical trials, InnoCan Pharma Corp shares C.INNO are trading unchanged at $0.25.